Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
|
29.4B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
298.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Shijiazhuang Yiling Pharmaceutical Co Ltd
Glance View
Shijiazhuang Yiling Pharmaceutical Co Ltd, rooted in the northern heart of China, embodies a harmonious blend of traditional Chinese medicine and modern pharmaceutical science. Born from the insightful vision of Wu Yiling, a prominent figure in integrating traditional Chinese medical practices with contemporary research methodologies, the company has grown into a significant player in the healthcare sector. Its foundation is deeply entrenched in leveraging ancient herbal wisdom while adopting cutting-edge biopharmaceutical technologies. At the core of its operations, Yiling Pharmaceutical specializes in the research, development, and production of therapeutic drugs aimed at treating chronic diseases and boosting immunity. This dual approach allows the company to carve out a niche in producing signature products like Lianhua Qingwen, a respiratory treatment renowned for its efficacy in alleviating symptoms from colds and flu. What powers Yiling Pharmaceutical's continued growth is its steadfast commitment to research and development, translated into a structured pipeline of innovative drugs. The company's funding funnel directs substantial resources into ongoing research, ensuring a constant expansion and refinement of their product portfolio. With an emphasis on effectiveness backed by rigorous scientific validation, Yiling has successfully navigated the complexities of pharmaceutical regulations, extending its reach beyond domestic borders to international markets. This expansionist strategy, coupled with a deep understanding of traditional medicine, forms a robust revenue stream, encapsulating both the domestic market's demand for traditional therapies and the international community's growing interest in alternative medicine solutions. Through these channels, Yiling harmonizes its traditional roots with a forward-thinking business model, ensuring steady financial footholds and promising horizons.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Shijiazhuang Yiling Pharmaceutical Co Ltd is 54.9%, which is above its 3-year median of 54.2%.
Over the last 3 years, Shijiazhuang Yiling Pharmaceutical Co Ltd’s Gross Margin has decreased from 60.3% to 54.9%. During this period, it reached a low of 46.5% on Dec 31, 2024 and a high of 63.6% on Dec 31, 2022.